Weitz & Luxenberg is currently accepting cases from people harmed by a faulty shoulder replacement device made by Zimmer Biomet. The medical device manufacturer issued…Read More
W&L Initiating Lawsuits on Behalf of Patients Harmed by XareltoOct. 29, 2014
Mounting evidence that the drug Xarelto increases the risk of brain hemorrhage, hemorrhagic stroke, gastrointestinal bleeding, and other forms of serious bleeding prompted leading national personal injury law firm W&L to today announce it is initiating cases on behalf of patients injured by this prescription medication.
Xarelto (rivaroxaban) is a specific type of Factor Xa inhibitor anticoagulant developed and manufactured by pharmaceutical companies Janssen and Bayer. It received FDA approval in 2011. Many patients take Xarelto to reduce the risk of deep-vein thrombosis and pulmonary embolism following knee- or hip-replacement surgery, while many more with atrial fibrillation are prescribed the medication to prevent strokes or other harmful clotting events.
However, Xarelto is in the same class of anticlotting medication as the drug Pradaxa (dabigatran), whose manufacturer was hit with more than 4,000 lawsuits after people who used the medication experienced uncontrolled bleeding. Pradaxa’s manufacturer, Boehringer Ingelheim, recently agreed to a $650-million settlement of the cases.
Xarelto’s manufacturers tout the drug as an improvement over older anticoagulants such as warfarin and heparin. Chiefly, they promote Xarelto’s dosing regimen — a once daily pill — and the lack of need for careful blood coagulation monitoring.
Yet, a growing body of scientific evidence coupled with a rising tally of adverse events reported to the FDA demonstrate the drug is unsafe and increases the risk of serious bleeds — particularly because serious bleeding, once it starts, can be nearly impossible to stop as Xarelto, unlike older anticoagulants, has no antidote.
The Institute for Safe Medication Practices, an independent nonprofit that examines medication use errors and the safety of medications, observed some months ago that Xarelto ended its first full year on the market as a Top 10 drug for generating complaints to the FDA.
Meanwhile, the FDA has twice rejected Janssen’s application to approve the drug for patients whose heart blood supply becomes dangerously constricted following an acute coronary event, the firm said. In addition, last year the FDA determined that consumer-oriented print ads touting Xarelto’s benefits were misleading, and this year the FDA required additional warning language for Xarelto’s package labeling, specifically relating to its risk of bleeding.
Xarelto victims can call a toll-free phone line to schedule a no-cost, no-obligation consultation with an attorney to explore their legal rights against the manufacturers of Xarelto. The number is (877) 625-5927.
Additionally, the firm announced the launch of a website that Xarelto victims can visit for details about the drug and increased bleeding risk. Visitors can also use the website to request that attorney consultation.
The website address is http://www.recallcenter.com/xarelto/